Lineage Cell Therapeutics (LCTX) Net Equity Issued and Repurchased (2011 - 2025)

Lineage Cell Therapeutics' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at -$5.2 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 62.14% year-over-year to -$5.2 million in Q4 2025; TTM through Mar 2026 was -$5.3 million, a 37.86% increase from a year earlier, with the FY2024 full-year figure at $68000.0, down 98.94% from the prior year.
• Net Equity Issued and Repurchased eased to -$5.2 million in Q4 2025 per LCTX's latest filing, from $5.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $19.9 million in Q1 2021 and bottomed at -$13.8 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $1.8 million (2021), against an average of $2.7 million.
• Across the five-year window, Net Equity Issued and Repurchased plunged 6845.23% in 2024 and surged 62.14% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $124000.0 in 2021, then grew by 19.35% to $148000.0 in 2022, then plunged by 234.46% to -$199000.0 in 2023, then plunged by 6845.23% to -$13.8 million in 2024, then jumped by 62.14% to -$5.2 million in 2025.
• Per Business Quant, the three latest LCTX Net Equity Issued and Repurchased figures stand at -$5.2 million (Q4 2025), $5.2 million (Q3 2025), and -$5.3 million (Q2 2025).